FDA Approves Ticagrelor (Brilinta) for DAPT in High-risk Pat
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The US Food and Drug Administration has approved ticagrelor (Brilinta/Brilique, AstraZeneca) for use with aspirin to cut the risk for a first myocardial infarction (MI) or stroke in high-risk patients with coronary artery disease (CAD) but no history of MI or stroke.

The new indication is based on the results of trials, in which such patients with both CAD and type 2 diabetes on dual-antiplatelet therapy (DAPT) that included ticagrelor 60 mg twice-daily showed a 10% drop in risk for major adverse cardiac events compared with aspirin alone over about 3 years.

Patients falling under the new indication do not need to have diabetes, although Phase III THALES trial had entered patients with diabetes and CAD, the latter defined as a 50% or greater narrowing of a coronary artery or a history of coronary revascularization but without a history of MI or stroke.

The benefit of DAPT with ticagrelor for the primary efficacy endpoint was more pronounced in a prespecified THEMIS subanalysis of more than 11,000 patients with a history of percutaneous coronary intervention.

Source: https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-approved-in-the-us-to-reduce-the-risk-of-a-first-heart-attack-or-stroke-in-high-risk-patients-with-coronary-artery-disease.html
Dr. S●●●●●m S●●●●y P●●●●●l and 5 others like this1 share
Like
Comment
Share
Dr. S●●●●●m S●●●●y P●●●●●l
Dr. S●●●●●m S●●●●y P●●●●●l General Medicine
Interesting read.
Jun 4, 2020Like1